Clinical trial
FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of…
NCT00323011 · University of Southern California, Other · Terminated
Key facts
| NCT number | NCT00323011 |
|---|---|
| Title | FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer |
| Official title | A Randomized Pilot Study of the Activation of the Hemostatic Pathway by FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer |
| Lead sponsor | University of Southern California, Other |
| Collaborators | Pfizer Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab |
| Enrollment | 5 |
| Start date | May 1, 2006 |
| Completion | Nov 1, 2007 |
| First posted | May 9, 2006 |
| Last update posted | May 21, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: